Metadherin, p50, and p65 Expression in Epithelial Ovarian Neoplasms: An Immunohistochemical Study

<table class="table-group" id="tab1"><tr><td><table class="table"><tr><td class="thead-hr" colspan="7"><hr/></td></tr><tr class="thead"><td align="left"> </td><td align="center">Grade 1</td><td align="center">Grade 2</td><td align="center">Grade 3</td><td align="center">Stage 1</td><td align="center">Stage 2</td><td align="center">Stage 3</td></tr><tr><td class="thead-hr" colspan="7"><hr/></td></tr><tr><td align="left">Epithelial ovarian carcinomas</td><td align="center">3</td><td align="center">8</td><td align="center">19</td><td align="center">7</td><td align="center">6</td><td align="center">17</td></tr><tr><td align="left">Borderline ovarian tumours</td><td align="center">n/a</td><td align="center">n/a</td><td align="center">n/a</td><td align="center">15</td><td align="center">0</td><td align="center">0</td></tr><tr><td align="left">Ovarian cystadenomas</td><td align="center">n/a</td><td align="center">n/a</td><td align="center">n/a</td><td align="center">n/a</td><td align="center">n/a</td><td align="center">n/a</td></tr><tr class="table-tr"><td colspan="7"><hr class="tbody-hr"/></td></tr></table></td></tr><tr class="table-fn"><td>
                FIGO: International Federation of Gynecology and Obstetrics.<br/></td></tr></table>

Clinicopathologic characteristics of epithelial ovarian tumours included. (Stage as per FIGO, 2009).

BioMed Research International

tab1

Table 1

Table 1: Metadherin, p50, and p65 Expression in Epithelial Ovarian Neoplasms: An Immunohistochemical Study 